[
1. Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl) 2019;236(2):545-59. doi:10.1007/s00213-018-5133-z
]Open DOISearch in Google Scholar
[
2. Meftah AM, Deckler E, Citrome L, Kantrowitz JT. New discoveries for an old drug: a review of recent Olanzapine research. Postgrad Med 2020;132(1):80-90. doi:10.1080/00325481.2019.1701823
]Open DOISearch in Google Scholar
[
3. Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf 2008;7(6):761-9. doi:10.1517/14740330802423234
]Open DOISearch in Google Scholar
[
4. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 2004;64(23):2709-26. doi:10.2165/00003495-200464230-00006
]Open DOISearch in Google Scholar
[
5. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62. doi:10.1016/S0140-6736(13)60733-3
]Open DOISearch in Google Scholar
[
6. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37(3):177-93. doi:10.2165/00003088-199937030-00001.10511917
]Open DOISearch in Google Scholar
[
7. Zyprexa Summary of Product Characteristics [Internet]. European Medicines Agency. Available from: https://www.ema.europa.eu/en/documents/product-information/zyprexa-epar-product-information_en.pdf
]Search in Google Scholar
[
8. EMEA/CPMP/EWP/QWP/1401/98. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London, January 2002.
]Search in Google Scholar
[
9. EMEA/CPMP/ICH/135/95. ICH Topic E6: Note for Guidance on Good Clinical Practice. London, January 1997.
]Search in Google Scholar
[
10. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal L 121, 01/05/2001 P. 0034 - 0044.
]Search in Google Scholar
[
11. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subject. Available from: https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2008.pdf.
]Search in Google Scholar
[
12. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15(6):657-80. doi:10.1007/BF01068419.3450848
]Open DOISearch in Google Scholar
[
13. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991;29(1):1-8.
]Search in Google Scholar
[
14. Hauschke D, Steinijans WV, Diletti E, et al. Presentation of the intrasubject coefficient of variation for sample size planning in bio-equivalence studies. Int J Clin Pharmacol Ther 1994;32(7):376-8.
]Search in Google Scholar
[
15. Himmerich H, Au K, Dornik J, Bentley J, Schmidt U, Treasure J. Olanzapine Treatment for Patients with Anorexia Nervosa. Can J Psychiatry 2017;62(7):506-7. doi:10.1177/0706743717709967.552899028683226
]Open DOISearch in Google Scholar
[
16. Davis LE, Attia E. Recent advances in therapies for eating disorders. F1000Res. 2019 26;8:F1000 Faculty Rev-1693. doi: 10.12688/f1000research.19847.1.676411631598212
]Open DOISearch in Google Scholar
[
17. Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Co-chrane Database Syst Rev 2018;9(9):CD012555. doi:10.1002/14651858.CD012555.pub2.651343730246876
]Open DOISearch in Google Scholar
[
18. Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Efficacy of Olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol 2017;83(7):1369-79. doi:10.1111/bcp.13242.546534528112422
]Open DOISearch in Google Scholar
[
19. Tanaka K, Inui N, Karayama M, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 2019;84(1):147-53. doi:10.1007/s00280-019-03868-5.31087137
]Open DOISearch in Google Scholar
[
20. Du P, Li P, Liu H, Zhao R, Zhao Z, Yu W, et al. Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions. Clin Pharmacol Drug Dev 2020;9(5):621-628. doi: 10.1002/cpdd.743.31595704
]Open DOISearch in Google Scholar
[
21. Chen Q, Zhang MQ, Liu Y, et al. Pharmacokinetics and bioequivalence of 2 tablet formulations of Olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study. Arzneimittelforschung 2012;62(11):508-12. doi:10.1055/s-0032-1323659.22933048
]Open DOISearch in Google Scholar
[
22. Cánovas M, Torres F, Domenech G, Cebrecos J, Pelagio P, Manríquez M, et al. Bioequivalence evaluation of two dosage forms of Olanzapine 10 mg formulations in healthy volunteers. Arzneimittelforschung 2011;61(2):75-9. doi: 10.1055/s-0031-1296170.21428240
]Open DOISearch in Google Scholar
[
23. Elshafeey AH, Elsherbiny MA, Fathallah MM. A single-dose, randomized, two-way crossover study comparing two Olanzapine tablet products in healthy adult male volunteers under fasting conditions. Clin Ther 2009;31(3):600-8. doi:10.1016/j.clinthera.2009.03.008.19393850
]Open DOISearch in Google Scholar
[
24. Singhal R, Thakkar V, Srivastava A. Evaluation of bioequivalence of two oral formulations of Olanzapine. Indian J Pharm Sci 2011;73(6):678-682. doi:10.4103/0250-474X.100249.348075623112405
]Open DOISearch in Google Scholar
